[1] [1] World Health Organization．WHO COVID-19 dashboard [EB/OL]．(2023-01-08)[2024-09-20]．https：//covid19.who.int/．

[2] [2] LAMB Y N．Nirmatrelvir plus ritonavir：first approval [J]．Drugs,2022，82 (5)：585-591．

[4] [4] SILVA S J RDA,NASCIMENTO J C FDO,MENDES R P G,et al．Two years into the COVID-19 pandemic：lessons learned [J]．ACS Infect Dis,2022,8 (9)：1758-1814．

[5] [5] SALETTI G,GERLACH T,JANSEN J M,et al．Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63 [J]．Sci Rep，2020，10 (1)：21447．

[6] [6] GAMBHIR R S，AGGARWAL A，BHARDWAJ A，et al．COVID-19 and mucormycosis (black fungus)：an epidemic within the pandemic [J]．Rocz Panstw Zakl Hig,2021,72 (3)：1-6．

[7] [7] MARZI M，VAKI LM K，BAHMANYAR M，et al．Paxlovid：mechanism of action，synthesis，andin silicostudy [J]．Biomed Res Int，2022：7341493．

[8] [8] OWEN D R，ALLERTON C M N，ANDERSON A S，et al．An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19 [J]．Science,2021,374 (6575)：1586-1593．

[9] [9] SHAH M M，JOYCE B，PLUMB I D，et al．Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States，April - September 2022 [J]．Am J Transplant,2023，23 (1)：150-155．

[11] [11] IncPfizer．Pfizer's novel COVID-19 oral antiviral treatment candidate reduced risk of hospitalization or death by 89% in interim analysis of phase 2/3 EPIC-HR study [EB/OL]．(2021-11-05) [2024-10-07]．https：//www.pfizer.com/news/press-release/press-release-detail/pfizers-novel-covid-19-oral-antiviral-treatment-candidate．

[12] [12] NIRAJ N，MAHAJAN S S，PRAKASH A，et al．Paxlovid：a promising drug for the challenging treatment of SARS-CoV-2 in the pandemic era [J]．Indian J Pharmacol，2023，54 (6)：452-458.

[13] [13] NAJJAR-DEBBINY R，GRONICH N，WEBER G，et al．Effectiveness of paxlovid in reducing severe coronavirus disease 2019 and mortality in high-risk patients [J]．Clin Infect Dis,2022,76(6)：1158-1165．

[14] [14] SHAO J S，FAN R，HU J R，et al．Clinical progression and outcome of hospitalized patients infected with SARS-CoV-2 Omicron variant in Shanghai，China [J]．Vaccines，2022，10 (9)：1409.

[15] [15] WANG Y，ZHAO D Y，LIU X B，et al．Early administration of Paxlovid reduces the viral elimination time in patients infected with SARS-CoV-2 Omicron variants [J]．J Med Virol,2023,95 (1)：e28443．

[16] [16] WEN W，CHEN C，TANG J K，et al．Efficacy and safety of three new oral antiviral treatment (molnupiravir，fluvoxamine and Paxlovid) for COVID-19：a meta-analysis [J]．Ann Med,2022,54 (1)：516-523．

[17] [17] BAI Y，DU Z W，WANG L，et al．Public health impact of paxlovid as treatment for COVID-19，United States [J]．Emerg Infect Dis,2024,30 (2)：262-269．